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The application of pluripotent stem-cell based in vitro models has become increasingly 
popular in medical research, especially for situations in which animal modeling is not sufficient 
to accurately describe the condition or for diseases where there is little research demonstrating 
the relationships between disease phenotype, pathological cellular mechanisms, and gene 
expression. Such is the case with Juvenile Osteochondritis Dissecans (JOCD), a degenerative 
bone disease that predominately affects the knee joints of children and progresses to early onset 
osteoarthritis. Previous research has involved the use of animal models or diseases similar to 
JOCD, but there has been little to no focus on the cellular mechanisms of this condition. 
Therefore, this study aimed to elucidate the cellular pathophysiology of JOCD as well as provide 
a test bed for future therapeutic interventions. We hypothesized that our iPSC in vitro models of 
JOCD would show protein dysfunction and accumulation in the rough endoplasmic reticulum as 




Juvenile Osteochondritis Dissecans (JOCD) is a disease involving the fragmentation of 
subchondral bone with no evidence of acute trauma, and it occurs primarily in the knee joint. 
Affecting mainly children and young adults, JOCD is becoming increasingly common and 
progresses into early onset osteoarthritis. As with many musculoskeletal diseases, the diagnosis 
of JOCD is highly dependent on imaging to identify lesions in the subchondral bone, and it is 
very difficult to ascertain whether a lesion is due to the disease or another cause. Once 
diagnosed, the general consensus of treatment options is based on either skeletal maturity or 
lesion stability, and little success has been reported (Edmonds & Polousky, 2013). The 
pathogenesis of the disease family, Osteochondritis Dissecans (OCD), is relatively well 
understood, but only relative to the tissue as a whole because there is little mention of cellular 
models in literature (Bruns et al., 2017).  
Although very few models of JOCD exist, Familial Osteochondritis Dissecans (FOCD) 
and OCD have been modeled in vitro with a focus on cellular pathology, demonstrating that a 
model of JOCD could have potential to characterize the disease. In 2008, Garvican et al. found a 
significant difference between OCD and normal chondrocytes in matrix protein expression, 
suggesting that future models of diseases in the OCD may find similar results. This led to Xu et 
al. creating a cellular model of the chondrogenesis of the disease in 2016, and they were able to 
characterize a major aspect of the disease from their results. They found a similar correlation 
between FOCD and the gene expression of matrix proteins. However, both models neglected to 
incorporate osteocytes into their models, which are important to accurately model the knee joint, 
especially for adolescent joints that are still developing. Because the lesions of JOCD start in the 
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subchondral bone, there may be an underlying pathogenesis in the endo-ossification of the tissue 
that contributes to its fragmentation, and the exact pathogenesis of JOCD cannot be completely 
assumed from the behavior of other diseases, leaving this area open for investigation.  
Induced pluripotent stem cells (iPSCs) have become a vital tool for modeling genetic 
diseases in vitro and have demonstrated rising importance in other applications as well. To be 
used for this purpose, they are usually patient-specific and differentiated into other cell types. 
They are then analyzed to determine the impact of the disease on development. Though they are 
typically used for diseases affecting other bodily systems such as in the cardiovascular and 
neurological fields, they have been shown to possess high potential for the musculoskeletal field. 
This area of study has typically been modeled using animal experiments or imaging techniques, 
and it is difficult to accurately model in vitro. Unfortunately, this leads to the neglect of 
musculoskeletal research involving techniques variant from the norm, more specifically the 
cellular mechanisms underlying disease development in the skeleton. Therefore, this study 
addressed the gap left by previous models through the development of an in vitro model of 











METHODS AND MATERIALS 
Cell Differentiation 
Fibroblasts were extracted and expanded from the skin biopsies of 2 healthy and 3 JOCD 
pediatric subjects; viral reprogramming and cloning of these cells generated 3 iPSC control lines 
and 9 iPSC disease lines. The disease lines were reprogrammed at the University of Washington 
in St. Louis, and the control lines were gifted from the Regenerative Medicine Institute at the 
National University of Ireland Galway. Two additional control iPSC lines were purchased from 
ATCC to increase the number of control lines to 5. Characterization of iPSCs using IHC, 
teratoma formation, PCR, and embryonic body formation confirmed the pluripotency of the 
lines. Subsequent differentiation into mesenchymal differentiation (iMSCs) using induction 
media was confirmed using FACs analysis, PCR, and multipotency tests. 
Using a 3-D pellet culture system, the iMSCs were divided into three groups and 
underwent an induction process during which they were fed media that contained specific growth 
factors to promote specific differentiation over several weeks of incubation. The pellets were 
cultured in round-bottom, 96-well plates, and the 200 µL of media per well was changed every 
other day, with the exception of weekends. They were fed media based on the schedule outlined 
in Figure 1. The first group was the control group, and it was fed basic MSC maintenance media 
throughout the culture period. The second group was fed media that promoted differentiation into 
cartilage (chondrogenesis). The third group was fed the same chondrogenic media for the first 21 









Figure 1: Schedule of the 3-D differentiation process. Chondro induction refers to feeding the organoids 
with chondrogenic media. Osteo induction refers to feeding the organoids with osteogenic media. 
 
Quantitative Analysis 
 Pellets from each group were washed in DPBS and either snap frozen at -80 degrees 
Celsius until digestion or immediately digested at day 0, 7, 14, 21, 28, 35, and 49 to quantify 
differentiation and disease progression. In order to measure chondrogenic differentiation, a 
Glycosaminoglycan (GAG) Assay was conducted to quantify the sulfated proteoglycans and 
glycosaminoglycan content, an important component of cartilage extracellular matrix. The 
pellets were snap frozen until use, digested in a papain solution overnight, and homogenized 
before carrying out experiments. The results of the assay were then normalized with the DNA 
content found using a DNA Picogreen Assay with the same samples. To measure the osteogenic 
differentiation, the pellets were digested in acetic acid solution overnight, homogenized, and 
used for a Calcium Assay to analyze calcium deposition. These results were normalized with the 







 Several pellets from each group were collected at the time points mentioned previously 
and fixed in 10% Formalin solution overnight for qualitative analysis. Once fixed, they were 
embedded in 5% agarose, dehydrated in 70% ethanol, and submitted for paraffin processing. 
They were then embedded in paraffin, sectioned using a microtome, and stained to assess cell 
distribution and morphology. Hematoxylin-eosin (H&E) staining was used to stain the cytoplasm 
and DNA within the cell nuclei. Toluidine blue staining dyed the cartilage and nuclei to verify 
the results of the GAG Assays; Alcian blue was used to visualize the cartilage formation of the 
cells. Immunofluorescent staining was used to visualize the distribution of extracellular matrix 

















Chondrogenic Differentiation  
 The GAG content of the chondrogenic organoids normalized by the DNA content is 
shown in Figure 2. There was no significant difference in GAG production between the control 
and JOCD pellets. This was found for both the day 21 time point and the day 49 time point. The 
data was analyzed using a two-way ANOVA with a one-way ANOVA post hoc for parametric 
data and a Kruskal-Wallis test for non-parametric data. Figure 3 shows the distribution of GAGs, 
appearing purple, within the pellets following staining with Toluidine Blue. As seen in Figure 4, 
the JOCD organoids appear to develop a shell of Col1 that is not present to the same degree in 
the normal organoid. The Aggrecan appears to be more concentrated in the center of the JOCD 








Figure 2: Level of GAG production measured as ug of GAG per ug of DNA. The results were shown at 












Figure 3: Toluidine Blue staining for GAG distribution in control and JOCD chondrogenic organoids. 
GAG is stained purple and cell nuclei appear dark pink. The images were taken at 20x magnification. The 















Figure 4: Immunostaining for ECM protein distribution in control and JOCD chondrogenic organoids. 
(A) Distribution of Col1 and Col2 in the organoids at day 21 and day 49. (B) Distribution of Aggrecan 
and cell nuclei (stained with DAPI) at day 21. The scale bars refer to 500um.  
 
Osteogenic Differentiation 
 The calcium deposition of the osteogenic organoids normalized by the DNA content is 
shown in Figure 5. The statistics were run similarly to the chondrogenic organoids mentioned 
above, and significance was found at p<0.001. There was a significant difference between the 
day 28, day 35, and day 49 time points for both the JOCD and control groups. However, there 
was no significant difference between the JOCD and control groups at any of the time points. 
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The immunostaining in Figure 6 shows that the osteogenic JOCD organoids do not seem to 










Figure 5: Level of calcium deposition measured as ug calcium per ug of DNA. Significance between time 

























Figure 6: Distribution of Col1 and Col2 in control and JOCD osteogenic organoids at day 21 (D21) and 













DISCUSSION AND FUTURE WORK 
 The result of the GAG assay suggests that there is no statistical difference in the 
production and deposition rates of the extracellular matrix protein between groups (Figure 2). 
This could be due to the inconsistent GAG distribution relative to cell content between diseased 
pellets, as shown in Figure 3. The control pellets appear to demonstrate a consistent distribution 
of GAG relative to the number of cell nuclei. In contrast, one of the JOCD pellets appears to 
possess a level of GAG relative to the number of nuclei that is less than the control, while the 
other pellet seems to possess a much greater ratio than the control (Figure 3). This variation 
between diseased cell lines could have led to the inconclusive results of the GAG assay, but 
more research is needed to support this hypothesis. The immunostaining demonstrates an 
obvious difference in the distribution of Col1 and Col2 throughout the organoids, as the diseased 
state of JOCD seems to cause collagen type one to form a thick shell around the pellet (Figure 4). 
This could be due to the inability of the diseased cartilage to regulate their extracellular matrix 
deposition throughout the organoid.  
 The Calcium assay also suggests that there is no significant difference in the production 
and deposition rates of calcium between groups (Figure 5). There is a significant difference 
between time points, but this is an expected characteristic that simply helps to confirm the 
osteogenic differentiation of the organoids and gives no insight into the diseased state. However, 
similarly to the chondrogenic analysis, the staining demonstrated an obvious difference in the 
deposition distribution of extracellular matrix proteins (Figure 6).  
 Future work could focus on quantifying the gene expression of ECM proteins and 
deposited substances, such as GAG and calcium. Quantifying the gene expression of Col1, Col2, 
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and Aggrecan in both the osteogenic and chondrogenic groups could also prove useful. This 
could demonstrate whether the production of these proteins is dysregulated as well. The 
histological staining of the calcium distribution throughout the osteogenic organoids would 
prove useful in further understanding the disease pathogenesis as well. Additionally, the analysis 
or imaging of the endoplasmic reticulum could show whether JOCD had a similar mechanism of 



















 These iPSC-based in vitro models of JOCD were able to recapitulate many aspects of the 
disease that allowed us to gain more understanding of the cellular pathogenesis. The quantitative 
analysis of several extracellular matrix deposits simply showed that the disease organoids were 
differentiating similarly to to the control, yet the qualitative analysis demonstrated the 
differences in the distribution as a result of the disease. This suggests that contrary to FOCD and 
previous understandings of the OCD family, the pathogenesis of JOCD may lie more in the 
distribution patterns of the extracellular matrix rather than the production rates. This novel 
understanding of the mechanisms by which the defective bone and cartilage develop would not 
have been possible without the use of these in vitro models, and they will further serve as a 
potential test bed to develop new treatments and progress deeper understanding of the OCD 
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